Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

4942 - Response assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: a comparison of RECIST 1.1, RANO and iRANO criteria


28 Sep 2019


Poster Display session 1


Tumour Site

Central Nervous System Malignancies


Emilie Le Rhun


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


E. Le Rhun1, F. Wolpert2, M. Fialek3, P. Devos4, N. Andratschke5, N. Reyns6, R. Dummer7, L. Mortier8

Author affiliations

  • 1 Neurology, Universitätsspital Zürich, 8091 - Zürich/CH
  • 2 Neurology, University Hospital and University of Zurich, Zurich/CH
  • 3 Dermatology Department, Lille University Hospital, Lille/FR
  • 4 Biostatistic Unit, Lille University Hospital, Lille/FR
  • 5 Radiotherapy, Universitätsspital Zürich, 8091 - Zürich/CH
  • 6 Neurosurgery, Lille University Hospital, Lille/FR
  • 7 Dermatology Department, Universitätsspital Zürich - Klinik für Dermatologie, 8091 - Zurich/CH
  • 8 Dermatology Department, Hopital Claude Huriez, 59037 - Lille/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4942


The evaluation of response for brain metastases (BM) may be challenging in the context of treatment by stereotactic radiotherapy (SRT) or immunotherapy or both, which represent major therapeutic options for melanoma BM.


We reviewed clinical and neuroimaging data of 62 melanoma patients with newly diagnosed BM treated by the combination of immunotherapy and SRT (n = 33, group A), immunotherapy alone (n = 10, group B) or SRT alone or in combination with other systemic therapies (BRAF inhibitors, n = 7; alkylating agents, n = 6; no systemic treatment, n = 6), (n = 19, group C). Response was assessed using RECIST 1.1, RANO or iRANO criteria.


BRAF mutations were noted in 26 patients. Until BM diagnosis, a median of 1 (range 1-4) line of systemic treatment was given. At BM diagnosis, median age was 58 years (range 23-85.5). Fifty-four patients (87%) had 1-3 metastases. The median maximum diameter was 18.5 mm (range, 9-49). The median DS-GPA was 3 (1-4). After a median follow-up of 30.5 months for surviving patients, 39 patients have experienced CNS progression, 16 (48.5%) in group A, 9 (90%) in group B, 14 (73.5%) in group C. Median PFS was 129.5 days (range 82-532) in group A, 75 days (range 35-203) in group B, 136 days (range 59-514) in group C. Forty-seven patients (76%) had died at the time of the analysis, 22 (66.5%) in group A, 7 (70%) in group B, 18 (94.5%) in group C. Median OS was 345 days (range 65-1824) in group A, 174.5 days (range 50-1361) in group B, 409 days (range 102-1244) in group C. 52 MRI scans were available for central review: pseudoprogression was documented in 9 patients (29%) in group A, 0 (0%) in group B, and 5 (29.5%) in group C. Response rates were similar with all three sets of response criteria. Progressive disease was less often called when applying iRANO to assess SRT target lesions.


While the retrospective nature and small sample size for subgroups are major limitations of this study, these data may indicate that the omission of SRT from first-line treatment may compromise outcome. Pseudoprogression is uncommon with immunotherapy alone; pseudoprogression rates were similar after SRT alone or in combination with immunotherapy or other systemic treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

University Hospital of Zurich.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.